Page 133 - 《中国药房》2022年6期

treated with chemotherapy[J]. J Clin Transl Res，2021，7 vest，2019，129（4）：1596-1611.
（2）：257-262. [42] MEYER S C. Mechanisms of resistance to JAK2 inhibi-
[32] IZZEDINE H，DEROSA L，LE TEUFF G，et al. Hyperten- tors in myeloproliferative neoplasms[J]. Hematol Oncol
sion and angiotensin system inhibitors：impact on out- Clin North Am，2017，31（4）：627-642.
come in sunitinib-treated patients for metastatic renal cell [43] SALMANINEJAD A，VALILOU S F，SHABGAH A G，et al.
carcinoma[J]. Ann Oncol，2015，26（6）：1128-1133. PD-1/PD-L1 pathway：basic biology and role in cancer im-
[33] MCKAY R R，RODRIGUEZ G E，LIN X，et al. Angioten- munotherapy[J]. J Cell Physiol，2019，234（10）：16824-
sin system inhibitors and survival outcomes in patients 16837.
with metastatic renal cell carcinoma[J]. Clin Cancer Res， [44] SYSOEVA V Y，AGEEVA L V，TYURIN-KUZMIN P A，
2015，21（11）：2471-2479. et al. Local angiotensin Ⅱ promotes adipogenic differentia-
[34] SORICH M J，KICHENADASSE G，ROWLAND A，et al. tion of human adipose tissue mesenchymal stem cells
Angiotensin system inhibitors and survival in patients through type 2 angiotensin receptor[J]. Stem Cell Res，
with metastatic renal cell carcinoma treated with VEGF- 2017，25：115-122.
targeted therapy：a pooled secondary analysis of clinical [45] GASIŪNIENĖ M，PETKUS G，MATUZEVIČIUS D，et al.
trials[J]. Int J Cancer，2016，138（9）：2293-2299. Angiotensin Ⅱ and TGF-β 1 induce alterations in human
[35] FIALA O，OSTAŠOV P，ROZSYPALOVÁ A，et al. Im- amniotic fluid-derived mesenchymal stem cells leading to
pact of concomitant cardiovascular medication on survival cardiomyogenic differentiation initiation[J]. Int J Stem
of metastatic renal cell carcinoma patients treated with Cells，2019，12（2）：251-264.
sunitinib or pazopanib in the first line[J]. Target Oncol， [46] JIANG X，WU F，XU Y，et al. A novel role of angiotensin
2021，16（5）：643-652. Ⅱ in epidermal cell lineage determination：angiotensin Ⅱ
[36] LIN Y T，WANG H C，TSAI M H，et al. Angiotensin Ⅱ re- promotes the differentiation of mesenchymal stem cells
ceptor blockers valsartan and losartan improve survival into keratinocytes through the p38 MAPK，JNK and JAK2
rate clinically and suppress tumor growth via apoptosis re- signalling pathways[J]. Exp Dermatol，2019，28（1）：59-
lated to PI3K/AKT signaling in nasopharyngeal carci- 65.
noma[J]. Cancer，2021，127（10）：1606-1619. [47] PAPINSKA A M，MORDWINKIN N M，MEEKS C J，et
[37] LIN Y T，WANG H C，CHUANG H C，et al. Pre-treat- al. Angiotensin-（1-7）administration benefits cardiac，re-
ment with angiotensin-（1-7）inhibits tumor growth via au- nal and progenitor cell function in db/db mice[J]. Br J
tophagy by downregulating PI3K/Akt/mTOR signaling in Pharmacol，2015，172（18）：4443-4453.
human nasopharyngeal carcinoma xenografts[J]. J Mol [48] PINTER M，JAIN R K. Targeting the renin-angiotensin
Med（Berl），2018，96（12）：1407-1418. system to improve cancer treatment：implications for im-
[38] QI R，LEI C G，BAI Y X，et al. The AT1/Raf/ERK1/2 sig- munotherapy[J]. Sci Transl Med，2017，9（410）：eaan5616.
naling pathway is involved in angiotensin Ⅱ-enhanced [49] VALLEJO-ARDILA D L，FIFIS T，BURRELL L M，et al.
proliferation of hepatic carcinoma cells[J]. Neoplasma， Renin-angiotensin inhibitors reprogram tumor immune mi-
2019，66（1）：83-91. croenvironment：a comprehensive view of the influences
[39] NI L，FENG Y，WAN H Y，et al. Angiotensin-（1-7）in- on anti-tumor immunity[J]. Oncotarget，2018，9（84）：
hibits the migration and invasion of A549 human lung 35500-35511.
adenocarcinoma cells through inactivation of the PI3K/ [50] LIU H，NAXEROVA K，PINTER M，et al. Use of angio-
Akt and MAPK signaling pathways[J]. Oncol Rep，2012， tensin system inhibitors is associated with immune activa-
27（3）：783-790. tion and longer survival in nonmetastatic pancreatic ductal
[40] DUTTA A，HUTCHISON R E，MOHI G. Hmga2 pro- adenocarcinoma[J]. Clin Cancer Res，2017，23（19）：
motes the development of myelofibrosis in Jak2 V617F knockin 5959-5969.
mice by enhancing TGF-β1 and Cxcl12 pathways[J]. Blood， [51] XIE G Z，CHENG T，LIN J，et al. Local angiotensin Ⅱ
2017，130（7）：920-932. contributes to tumor resistance to checkpoint immunothe-
[41] STIVALA S，CODILUPI T，BRKIC S，et al. Targeting rapy[J]. J Immunother Cancer，2018，6（1）：88.
compensatory MEK/ERK activation increases JAK inhibi- （收稿日期：2021-08-19 修回日期：2022-02-28）
tor efficacy in myeloproliferative neoplasms[J]. J Clin In- （编辑：胡晓霖）

中国药房 2022年第33卷第6期 China Pharmacy 2022 Vol. 33 No. 6 ·763 ·